GlassScriptPhysician profile
Tracee J Lucas
NPI 1376114959
$10,488.30
in general payments reported to CMS, 2019-2025
30 companies · $3,268 in 2025
The $3,268 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $292 · 2022: $1,334 · 2023: $2,870 · 2024: $2,725 · 2025: $3,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,774 · Education: $88.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,774.38 |
| Education | $88.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,695.76 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,280.25 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,092.56 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $915.23 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $772.35 | 2022-2025 | Rexulti |
| Corium, LLC | $600.05 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $536.89 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Axsome Therapeutics, INC. | $487.76 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $422.65 | 2023-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $365.32 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $342.57 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $337.65 | 2021-2025 | Ingrezza |
| Almatica Pharma LLC | $325.68 | 2023-2025 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $306.62 | 2022-2024 | Jornay Pm |
| Bausch Health US, LLC | $128.22 | 2023-2025 | Aplenzin |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $118.95 | 2022 | |
| Livanova USA, INC. | $113.72 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Sunovion Pharmaceuticals INC. | $94.02 | 2022 | |
| Idorsia Pharmaceuticals US INC | $73.36 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $64.20 | 2023-2024 | Xelstrym, Secuado |
| Vertical Pharmaceuticals, LLC | $60.39 | 2025 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $54.69 | 2023-2024 | Trintellix |
| Neos Therapeutics, LP | $51.64 | 2023-2024 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $51.39 | 2024 | Fanapt |
| Tempus Ai, INC | $43.94 | 2025 | Tempus Pixel |
| Indivior INC. | $39.15 | 2022-2023 | Perseris |
| Neuronetics, INC. | $34.79 | 2025 | Neurostar Tms Therapy System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.51 | 2025 | Rejoyn |
| Biogen, INC. | $24.97 | 2024 | |
| Collegium Pharmaceutical, INC. | $21.02 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracee Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.